Edison Inks Potential $4.3B R&D Deal With Japan Pharma Co.

Law360, New York (January 31, 2014, 8:17 PM EST) -- California-based Edison Pharmaceuticals Inc. said Friday that it has entered into a strategic alliance with Japan’s Dainippon Sumitomo Pharma Co. Ltd. potentially worth up to $4.3 billion to develop drugs targeting cellular energy metabolism.

Under the terms of the agreement, DSP will gain select development and commercialization rights in Japan and North America to jointly discovered drugs in exchange for $10 million upfront and $40 million in research and development support, Edison said in a statement.

“Our partnership with DSP codifies a common vision for developing...
To view the full article, register now.